Analysis for the efficacy and safety of peginterferon-alpha-2a monotherapy on chronic active hepatitis B patients - Peginterferon-alpha-2a monotherapy in patients with chronic hepatitis B

Department of general internal medicine, Kyushu-University hospital0 个研究点目标入组 50 人开始时间: 2015年6月23日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Patients with the following are excluded: 1. Patients who are taking herbal medicine, syo-saiko-to. 2. Previous history of interstitial pneumonia. 3. Other chronic liver diseases such as autoimmune hepatitis, alcoholic liver disease. 4. Previous history of hypersensitivity to peginterferon-alpha-2a or other interferon products. 5. Previous history of hypersensitivity to biologicals such as vaccines. 6. Liver cirrhosis, liver failure and hepatocellular carcinoma. 7. Patients who have hepatic encephalaopathy, esophageal varices, ascites, or those previous history. 8. Patients who have autoimmune diseases such as hemolytic anemia, ulcerative colitis, rheumatoid arthritis, or those previous history. 9. Patients who have heart diseases difficult to control. 10. Patients who have depression, epileptic seizure, or mental disorders with continuous treatment, or those previous history. 11. Uncontrollable hypertension. 12. Previous history of cerebrovascular diseases such as brain infarction, cerebral hemorrhage, subarachnoid hemorrhage or transient ischemic attack. 13. Diabetes mellitus receiving medical treatment. 14. Patients who are pregnant or lactating women. 15. Patients who are receiving nucleotide analogues treatments within three months. 16. Patients who are disquialified to participate in this trial judged by attending physician.

发起方

Department of general internal medicine, Kyushu-University hospital